ProfileJobs

Insulet Corporation

HealthManufacturing & IndustrialTechnologydiabeteshealthtechmanufacturermedical devices

Insulet Corporation (NASDAQ: PODD) is an innovative medical device company dedicated to making the lives of people with diabetes easier. Through its OmniPod Insulin Management System, Insulet seeks to expand the use of insulin pump therapy among people with insulin-dependent diabetes. The OmniPod is a revolutionary and easy-to-use tubeless insulin pump that features just two parts and a fully-automated cannula insertion. Insulet's Delivery Systems business also partners with global pharmaceutical and biotechnology companies to tailor the OmniPod technology platform for the delivery of subcutaneous drugs across multiple therapeutic areas.

 Founded in 2000, Insulet Corporation is based in Billerica, Massachusetts.

Revenue(Q1, 2017)
$101.7 M
Market capitalization(2017-08-17)
$3.2 B
Company Growth (employees)
Type
Public
HQ
Billerica, US
Founded
2000
Size (employees)
640 (est)
Website
insulet.com
Insulet Corporation was founded in 2000 and is headquartered in Billerica, US

Insulet Corporation Office Locations

Insulet Corporation has offices in Billerica, Denver, Tulsa, Washington and in 11 other locations
Billerica, US (HQ)
200 600 Technology Park Dr
Show all (15)

Insulet Corporation Data and Metrics

Insulet Corporation Financial Metrics

Insulet Corporation's revenue was reported to be $101.7 m in Q1, 2017
USD

Revenue (Q1, 2017)

101.7 m

Gross profit (Q1, 2017)

59.4 m

Gross profit margin (Q1, 2017), %

58%

Net income (Q1, 2017)

(10 m)

EBIT (Q1, 2017)

(5.3 m)

Market capitalization (17-Aug-2017)

3.2 b

Cash (31-Mar-2017)

76 m
Insulet Corporation's current market capitalization is $3.2 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

247.1 m288.7 m324.2 m367 m

Revenue growth, %

17%12%13%

Cost of goods sold

134.7 m145.4 m176.1 m155.9 m

Gross profit

112.4 m143.3 m148.2 m211.1 m

Gross profit Margin, %

45%50%46%58%

Sales and marketing expense

94.5 m

R&D expense

55.7 m

General and administrative expense

71.6 m

Operating expense total

141.5 m155.6 m208.9 m221.8 m

EBIT

(29.1 m)(12.3 m)(60.8 m)(10.7 m)

EBIT margin, %

(12%)(4%)(19%)(3%)

Interest expense

17.2 m14.7 m12.6 m14.4 m

Interest income

124 k129 k16.1 m

Pre tax profit

(44.9 m)(51.4 m)(73.2 m)(26.8 m)

Income tax expense

(100 k)(142 k)(291 k)(392 k)

Net Income

(45 m)(51.5 m)(73.5 m)(28.9 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

72 m75 m61.2 m75.6 m87.3 m81.2 m87.3 m94.9 m101.7 m

Cost of goods sold

36.2 m36.9 m28.4 m41.2 m51.7 m37.2 m36.9 m39.2 m42.3 m

Gross profit

35.8 m38 m32.8 m34.4 m35.7 m44.1 m50.5 m55.6 m59.4 m

Gross profit Margin, %

50%51%54%45%41%54%58%59%58%

Sales and marketing expense

14.9 m14.9 m17.4 m21.8 m24.2 m24 m23 m22.1 m28.1 m

R&D expense

6.7 m7.2 m8.2 m12.1 m10 m13 m13 m13.7 m17.5 m

General and administrative expense

19.5 m18.9 m15.8 m12.9 m17.2 m14.7 m15.8 m17.3 m19.1 m

Operating expense total

41 m40.9 m41.4 m46.7 m51.4 m51.8 m51.7 m53.2 m64.7 m

EBIT

(5.3 m)(2.9 m)(8.6 m)(12.4 m)(15.7 m)(7.7 m)(1.3 m)2.4 m(5.3 m)

EBIT margin, %

(7%)(4%)(14%)(16%)(18%)(9%)(1%)3%(5%)

Interest expense

(4 m)(3 m)(3.2 m)(3.1 m)(3.2 m)(3.1 m)3.1 m3 m5 m

Interest income

29 k32 k36 k41 k46 k

Pre tax profit

(29.1 m)(10.8 m)(11.8 m)(15.4 m)(18.9 m)(10.6 m)(4.3 m)(3 m)(9.9 m)

Income tax expense

(52 k)(21 k)(52 k)(37 k)(62 k)(64 k)65 k66 k96 k

Net Income

(35.3 m)(46.1 m)(11.8 m)(27.3 m)(46.2 m)(12.5 m)(16.7 m)(19.8 m)(10 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

149.7 m151.2 m122.7 m137.2 m

Accounts Receivable

33.1 m39.9 m48.4 m28.8 m

Inventories

9.5 m13.1 m5.7 m35.5 m

Current Assets

198.2 m208.2 m190.8 m370 m

PP&E

32.4 m37.1 m41.8 m46.3 m

Goodwill

37.5 m37.5 m39.7 m39.7 m

Total Assets

288 m302.2 m275.1 m456.6 m

Accounts Payable

19.4 m14.7 m18.6 m13.2 m

Total Debt

116.3 m167.4 m177.2 m269 k

Current Liabilities

42.4 m44.3 m65.2 m55.7 m

Total Liabilities

393.5 m

Additional Paid-in Capital

651.1 m661.8 m686.2 m744.2 m

Retained Earnings

(526.5 m)(578 m)(651.5 m)(680.4 m)

Total Equity

124.6 m83.8 m34.1 m63.2 m

Debt to Equity Ratio

0.9 x2 x5.2 x0 x

Debt to Assets Ratio

0.4 x0.6 x0.6 x0 x

Financial Leverage

2.3 x3.6 x8.1 x7.2 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

175.5 m146.4 m145.6 m145.1 m145.5 m111.6 m75.7 m215.4 m76 m

Accounts Receivable

41.8 m47.1 m36.1 m31.8 m31.8 m40.5 m38.7 m38.5 m40.6 m

Inventories

8.8 m9.7 m20.1 m23.4 m13 m14 m24.5 m32.7 m34.3 m

Current Assets

231.8 m206.6 m205.4 m203.8 m194.3 m171.8 m181.3 m361.8 m337.2 m

PP&E

34.2 m36.6 m44.6 m42 m41.5 m41.7 m41.1 m50.9 m65.3 m

Goodwill

37.5 m37.5 m37.5 m37.5 m39.8 m39.8 m39.8 m39.7 m39.7 m

Total Assets

325.3 m301.2 m305.7 m300.4 m293.1 m254.8 m263 m453.2 m445 m

Accounts Payable

18.6 m17.7 m14.2 m17.9 m15.6 m13.5 m21.6 m18.2 m6.4 m

Current Liabilities

71.2 m47.8 m47.4 m52.7 m59.4 m49.8 m55.2 m54.3 m39.4 m

Additional Paid-in Capital

639.6 m652.9 m670.5 m675.5 m679.8 m690.6 m695.9 m736.7 m754.6 m

Retained Earnings

(561.8 m)(572.6 m)(589.9 m)(605.3 m)(624.2 m)(664 m)(668.2 m)(671.3 m)(690.4 m)

Total Equity

70.3 m55.1 m26.4 m27.4 m65.1 m63.6 m

Financial Leverage

4.3 x5.3 x9.7 x9.6 x7 x7 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(45 m)(51.5 m)(73.5 m)(28.9 m)

Depreciation and Amortization

11.8 m12.2 m15.8 m13.8 m

Accounts Receivable

(4.5 m)(10 m)(9.8 m)12.6 m

Inventories

5.4 m(3.6 m)(722 k)(24.1 m)

Cash From Operating Activities

3.3 m8.9 m(12.6 m)15.9 m

Purchases of PP&E

(7.3 m)(11.5 m)(10.6 m)(22.1 m)

Cash From Investing Activities

(7.3 m)(11.5 m)(15.3 m)(178 m)

Short-term Borrowings

(153.6 m)

Cash From Financing Activities

96.4 m4 m(371 k)176.6 m

Interest Paid

5.7 m4.6 m4 m3.7 m

Income Taxes Paid

321 k124 k109 k932 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(35.3 m)(46.1 m)(11.8 m)(27.3 m)(46.2 m)(12.5 m)(16.7 m)(19.8 m)(10 m)

Depreciation and Amortization

6.1 m9.2 m3.4 m7.1 m11.4 m3.4 m6.8 m10.5 m3.3 m

Accounts Receivable

(10.5 m)(16.7 m)3.5 m6.9 m5.3 m2.3 m3.7 m3 m(12.1 m)

Inventories

699 k(198 k)(7 m)(10.3 m)312 k(2.6 m)(13.1 m)(21.3 m)1.2 m

Cash From Operating Activities

(509 k)4.3 m(3.5 m)(2.7 m)(10.5 m)(6.8 m)(4.2 m)(21.8 m)

Purchases of PP&E

(5.7 m)(8.9 m)(4.3 m)(4.6 m)(7.1 m)(3.2 m)(5.9 m)(19.2 m)

Cash From Investing Activities

(5.7 m)(8.9 m)(4.3 m)(4.6 m)(11.8 m)1.5 m(35.8 m)(80.8 m)(42.3 m)

Short-term Borrowings

(153.6 m)

Long-term Borrowings

(160.7 m)(189.5 m)

Cash From Financing Activities

32.1 m1.2 m2.2 m1.2 m292 k(2.2 m)(4.6 m)177.6 m2.9 m
USDY, 2017

Revenue/Employee

158.9 k

Financial Leverage

7 x

Insulet Corporation Operating Metrics

FY, 2016

Patents Issued

23

Patents Pending

32

Insulet Corporation Market Value History

Insulet Corporation Revenue Breakdown

Market Position of Insulet Corporation

Competitors

ATRION Corporation
Health - Public
Abyrx
Health - Private
CannaKorp
Technology - Private
Intuity Medical
Health - Private
Compare competitors

Traffic Overview of Insulet Corporation

Insulet Corporation Online and Social Media Presence

Insulet Corporation Company Life and Culture

You may also be interested in